Risk stratification models for allogeneic SCT in adult Ph/BCR::ABL1-negative (Ph–) ALL (European study groups)
| National Study Group . | Patient age (y) . | Risk stratification criteria∗ . | |||
|---|---|---|---|---|---|
| Postinduction MRD . | Cytogenetics/genetics† . | WBC (×109/L) . | Miscellaneous . | ||
| GMALL (Germany) | <55 | ≥0.01% after consolidation (wk 16 onward) | KMT2A+ | >30 (B) | Late CR, pro-B, early/mature-T |
| GIMEMA (Italy) | ≤65 | ≥0.01% after early consolidation (wk 10-16), any positivity (wk 22) | Adverse, KMT2A+ | >100 | Early/mature-T |
| HOVON (The Netherlands) | <40 | ≥0.01% after consolidation (wk 14-16) | Adverse KMT2A, hypodiploidy, complex karyotype | >30 (B), >100 (T) | Late CR |
| PALG (Poland) | <55 | ≥0.1% after induction ≥0.01% during/after consolidation | KMT2A+ | >30 (B), >100 (T) | CNS+ |
| UK NCRI ALL Group (United Kingdom) | <40 | ≥0.1% after induction and consolidation (mathematical risk model integrating MRD, cytogenetics and WBC) | Adverse | High count | — |
| FALL (Finland) | <45 | ≥0.1% after consolidation block B | Abn11q23, hypodiploidy | >100 | Late CR, d15 BM blasts >25% |
| RALL (Russia) | <55 | Positive during/after consolidation | t(4;11), t(1;19), KMT2A+ | — | Age >30 |
| SVALL (Sweden) | <65 | ≥0.1% after consolidation | Hypodiploidy, KMT2A+ | — | EOI BM blasts >5% |
| PETHEMA (Spain) | <55 (60 fit) | ≥0.1% after induction ≥0.01% during/after consolidation | — | — | — |
| GRAALL (France/Belgium/Switzerland) | <60 | ≥0.1% after induction at wk 6 or ≥0.01% after consolidation at wk 12 | — | — | — |
| CELL (Czech Republic) | <65 | ≥0.1% after induction ≥0.01% after consolidation | KMT2A+ | >30 (B) | Early/mature-T |
| National Study Group . | Patient age (y) . | Risk stratification criteria∗ . | |||
|---|---|---|---|---|---|
| Postinduction MRD . | Cytogenetics/genetics† . | WBC (×109/L) . | Miscellaneous . | ||
| GMALL (Germany) | <55 | ≥0.01% after consolidation (wk 16 onward) | KMT2A+ | >30 (B) | Late CR, pro-B, early/mature-T |
| GIMEMA (Italy) | ≤65 | ≥0.01% after early consolidation (wk 10-16), any positivity (wk 22) | Adverse, KMT2A+ | >100 | Early/mature-T |
| HOVON (The Netherlands) | <40 | ≥0.01% after consolidation (wk 14-16) | Adverse KMT2A, hypodiploidy, complex karyotype | >30 (B), >100 (T) | Late CR |
| PALG (Poland) | <55 | ≥0.1% after induction ≥0.01% during/after consolidation | KMT2A+ | >30 (B), >100 (T) | CNS+ |
| UK NCRI ALL Group (United Kingdom) | <40 | ≥0.1% after induction and consolidation (mathematical risk model integrating MRD, cytogenetics and WBC) | Adverse | High count | — |
| FALL (Finland) | <45 | ≥0.1% after consolidation block B | Abn11q23, hypodiploidy | >100 | Late CR, d15 BM blasts >25% |
| RALL (Russia) | <55 | Positive during/after consolidation | t(4;11), t(1;19), KMT2A+ | — | Age >30 |
| SVALL (Sweden) | <65 | ≥0.1% after consolidation | Hypodiploidy, KMT2A+ | — | EOI BM blasts >5% |
| PETHEMA (Spain) | <55 (60 fit) | ≥0.1% after induction ≥0.01% during/after consolidation | — | — | — |
| GRAALL (France/Belgium/Switzerland) | <60 | ≥0.1% after induction at wk 6 or ≥0.01% after consolidation at wk 12 | — | — | — |
| CELL (Czech Republic) | <65 | ≥0.1% after induction ≥0.01% after consolidation | KMT2A+ | >30 (B) | Early/mature-T |